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Abstract: Early understanding of the pharmacokinetics and metabolic patterns of new drug candidates is essential for selection
of optimal candidates to move further in to the drug development process. In vitro methodologies can be used to investigate met-
abolic patterns, but in general, they lack several aspects of the whole-body physiology. In contrast, the complexity of intact ani-
mals does not necessarily allow individual processes to be identified. Animal models lacking a major excretion organ can be
used to investigate these individual metabolic processes. Animal models of nephrectomy and hepatectomy have considerable
potential as tools in preclinical pharmacokinetics to assess organs of importance for drug clearance and thereby knowledge of
potential metabolic processes to manipulate to improve pharmacokinetic properties of the molecules. Detailed knowledge of anat-
omy and surgical techniques is crucial to successfully establish the models, and a well-balanced anaesthesia and adequate moni-
toring of the animals are also of major importance. An obvious drawback of animal models lacking an organ is the disruption of
normal homoeostasis and the induction of dramatic and ultimately mortal systemic changes in the animals. Refining of the surgi-
cal techniques and the post-operative supportive care of the animals can increase the value of these models by minimizing the
systemic changes induced, and thorough validation of nephrectomy and hepatectomy models is needed before use of such models
as a tool in preclinical pharmacokinetics. The present MiniReview discusses pros and cons of the available techniques associated
with establishing nephrectomy and hepatectomy models.
Knowledge of pharmacokinetics and metabolism patterns is
essential in the selection of new drug candidates. In the past,
many drug candidates have been discontinued from further
development due to unfavourable pharmacokinetics in man
[1]. Thus, early insight into metabolism and clearance path-
ways may be able to improve drug design, including which
organs and receptors that contribute to the clearance process.
Catabolic patterns play an important role in potential drug can-
didate modification because these affect drug clearance and
can be used to obtain a suitable plasma half-life. Thus, being
a key factor in determination of dosage regimen, the drug
half-life ultimately influences important issues such as patient
compliance, for example, when dosage intervals are short [2].
Many different in vitro methodologies can be used to pre-
dict in vivo clearance, but in general, in vitro methods lack
several aspects of the complex whole-body clearance. Insuffi-
ciencies in the prediction of in vivo metabolic clearance based
on in vitro methods often include lack of account for extrahe-
patic metabolism, active transporter mechanism in primary
clearance organs and adaptive physiology or time- or dose-
dependent kinetics [2].
On the other hand, pharmacokinetic studies in intact animals
sometimes give rise to highly complex elimination patterns
that do not necessarily allow individual processes to be identi-
fied. In such cases, complete or partial removal of a major
excretion organ such as liver or kidneys can be helpful to shed
light on the specific clearance mechanisms of the drug in
question. Indeed, nephrectomy and hepatectomy have been
used as models in pharmacokinetic studies to investigate clear-
ance mechanism of many different drugs and potential drug
candidates [3–11]. For example, the use of a hepatectomized
rat model has clearly demonstrated that the elimination of pen-
tobarbital proceeds primarily via hepatic metabolism [11].
Nephrectomized rats have been used to estimate clearance
ratios of various drugs, demonstrating the importance of renal
function in their elimination [5]. Animal models of nephrec-
tomy and hepatectomy have also been used to study the
metabolism of endogenous substances to improve the general
biological insight. Thus, for example, the metabolism of para-
thyroid hormone has been studied in both nephrectomized rats
and hepatectomized rats [12]. Removal of an organ can shed
some light on which organs partake in synthesis of endoge-
nous substances, for instance a hepatectomy model in pigs has
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been used to demonstrate up-regulation of FVIII synthesis in
extrahepatic tissue [3].
Basically, the removal of an organ can give two important
pieces of information regarding clearance mechanisms. First, it
clearly demonstrates to which extent the organ of choice is
clearing the compound under investigation; second, it shows
to what extent the compound is cleared outside the organ.
Both are highly relevant in the development of potential drug
candidates, and moreover, this information can be used to
determine dosage and dosage intervals of a given drug used in
human beings with impaired organ function.
Regardless of the benefits of surgical models, the obvious
downside of such models is their massively invasive nature
that induces dramatic and ultimately mortal systemic changes
in the animals employed. The changes induced are characteris-
tic of organ failure, and therefore, animal models lacking an
organ have commonly been used for this purpose in particular.
Thus, on top of the technical challenges involved in employ-
ing surgical models in pharmacokinetic studies, the time
dependency of the obtained data often complicates their inter-
pretation. This MiniReview will focus on surgical models of
nephrectomy and hepatectomy and the pros and cons of their
use as preclinical tools to investigate the clearance mechanism
of potential drug candidates.
Nephrectomy
Nephrectomy means surgical removal of the kidneys and is
often termed ‘bilateral nephrectomy’ to emphasize that both kid-
neys are removed. Nephrectomy has been used as a model of
acute renal failure [13], whereas partial nephrectomies, typically
5/6 nephrectomies, have been used to study chronic renal failure
[14]. Nephrectomy models have also been used in metabolism
and clearance studies [4,5,12,15,16]. Rats and mice are most
commonly used for nephrectomy, but other species have also
been employed (table 1). A broad range of drugs have been
studied in nephrectomized rats, and the obtained data clearly
demonstrate the varying importance of renal clearance (fig. 1).
These experiments were performed to predict clearance of these
drugs in patients with renal insufficiency [5]. The clearance of
romiplostim in rats showed important dose dependencies, the
kidneys playing a predominant role in the clearance of high
doses but only minor at lower doses [4]. Thus, dose-dependent
clearance mechanisms are important to keep in mind when using
such animal models. Metabolism of endogenous parathyroid
hormone has also been studied in nephrectomized rats. Segre
and coworkers used 125I-labelled parathyroid hormone to nicely
outline the relative importance of kidneys and liver in its clear-
ance (fig. 2) [12].
Inulin is considered the gold standard of exogenously
administered markers for measuring glomerular filtration rate
(GFR) [17]. Glomerular filtration rate has been studied in
nephrectomized mice by the means of inulin clearance, and as
expected, both GFR and inulin clearance were found to be
abolished [15]. However, conflicting findings have also been
reported [16]. As a pharmacokinetic model, nephrectomy can
be used to assess renal and extrarenal clearance.
Anatomical challenges when doing nephrectomy. The
anatomy of the kidneys rarely causes problems when
performing nephrectomy. Three structures need to be ligated
to remove the kidneys, the renal artery, the renal vein and the
Table 1.
Studies using nephrectomy models including species, survival time after establishment, study aim and anaesthetic agents used.
Species Survival Aim
Anaesthetic and
analgesic agents Investigators
Rat 3–4 days Effect of aluminium hydroxide gel
on the survival time and on the blood
levels of sulphates, phosphates, calcium,
urea and cholesterol after bilateral
nephrectomy.
Diethyl ether Rosenkranz [68]
45–48 hr1 Study of parathyroid hormone metabolism Not reported Segre et al. [12]
Not reported Study of renal and extrarenal
elimination rate of varies drugs
Pentobarbital Moravek et al. [5]
Not reported Protein metabolism in renal failure model Diethyl ether Holecek et al. [69]
Not reported Pharmacokinetics of romiplostim Induction: pentobarbital
Maintenance: methoxyflurane
Wang et al. [4]
Mouse Not reported Determine the role of the kidney and acute renal
failure in influencing serum cytokines and
pulmonary homoeostasis
Avertin (2,2,2-tribromoethanol) Hoke et al. [13]
Not reported Serial determination of glomerular filtration rate Ketamine and xylazine Qi et al. [15]
Not reported Study of anaesthetics protection against liver and
intestine injury after acute kidney injury
Pentobarbital Kim et al. [20]
Pig Not reported Extrarenal clearance of iohexol,
inulin, and 51Cr-EDTA
Pre-medication: azaperone
Induction: thiopental Maintenance:
thiopental or ketamine and midazolam
Frennby et al. [70]
Not reported Biliary and total extrarenal clearance
of inulin and iohexol
Pre-medication: azaperone Induction
and maintenance: thiopental
van Westen et al. [16]
Sheep Not reported Pharmacokinetic study of 125I-erythropoietin Pentobarbital Widness et al. [71]
1Not survival time, but rather time in experiment, that is, indicating a survival for at least this long.
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ureter (fig. 3). It is important not to harm or interrupt the
adrenal glands and their blood supply as they are in close
proximity to the kidneys. Thus, special attention must be on
a. renalis rami adrenales caudales and v. renalis ramus
adrenalis caudalis, due to their direct connection to the blood
supply of the kidneys.
Anaesthesia. A wide range of anaesthetics have been used in
nephrectomy studies in the literature, unfortunately without
particular attention on describing why the given anaesthetic was
chosen (table 1). Anaesthetics and analgesics that are
metabolized in the liver can sometimes cause problems in
nephrectomized animals. If pharmacologically active
metabolites are formed and these are cleared by the kidneys,
nephrectomy will result in unpredictable plasma concentrations
that can affect the depth of anaesthesia. As an example,
morphine gives rise to the active metabolite morphine-6-
glucuronide, which is cleared via the kidneys [18]. The effect of
opioid metabolites has been reviewed elsewhere [19]. As
discussed below, extrarenal clearance can be influenced by
chronic renal failure. However, although extrarenal clearance
could potentially influence the anaesthetic and analgesic effect
in animals undergoing nephrectomy, the time delay from
nephrectomy establishment to observed changes in extrarenal
clearance will in most cases limit its relevance in
pharmacokinetic studies. It has been shown that choice of
anaesthesia can influence and even protect against hepatic and
intestinal injury after nephrectomy [20] underlining its
importance in such models. In spite of this, renal clearance
seems to play a minor role for most anaesthetics, and therefore,
the range of agents used for nephrectomy studies is quite similar
to that available for animals with normal renal function.
However, choosing an inhalation anaesthetic like isoflurane that
is primarily eliminated via the lungs may still be a good choice
to avoid even the slightest risk of undesired changes in
elimination of the anaesthetic agents used.
Monitoring. When doing surgery on laboratory animals, one
should always consider what to monitor both intraoperatively
and post-operatively. Proper monitoring is necessary to keep
track of the well-being of the animal, and parameters commonly
used in nephrectomy studies are listed in table 2. Blood urea
nitrogen (BUN) is mainly cleared by the kidneys and is
considered a good marker of renal function, particularly in cases
with decreased urine flow [21]. Another important biochemical
marker, plasma creatinine, is frequently used clinically to assess
renal function [22]. Creatinine is generated endogenously from
creatine at a constant rate and is solely excreted by the kidneys
Fig. 1. Elimination ratio (ER) versus renal function for various drugs.
Elimination rates were measured in animals with varying degree of
renal function and compared with control animals with normal renal
function. ER is defined as the ratio of the measured elimination rate
constant during decreased renal function to that of control animals.
The figure shows that lithium, amikacin, gentamicin and tobramycin
are primarily cleared via the kidneys; ceftriaxone and cefoperazone are
to some degree cleared via the kidneys, whereas theophylline and
mesocain have very little or no renal clearance. The figure is modified
from Ref. [5].
Fig. 2. Concentration versus time curve of 125I-labelled parathyroid
hormone in sham-operated, hepatectomized and nephrectomized rats.
While both liver and kidney play a role in the elimination kinetics of
parathyroid hormone, the liver is shown to have most impact on the
course of concentration versus time curve. Unbroken line with filled
circles: sham-operated rats, cross with broken line: nephrectomized
rats and open circles with dotted line: hepatectomized rats. The figure
is modified from Ref. [12].
Fig. 3. Diagram of the kidneys, adrenal glands, ureters and blood ves-
sels of interest when performing nephrectomy. The diagram is based
on the anatomy of the rat with placement of ligatures needed for
nephrectomy (arrows). 1: kidneys, 2: adrenal glands, 3: inferior vena
cava, 4: abdominal aorta, 5: ureters, 6: renal veins, 7: renal arteries, 8:
adrenal veins, 9: adrenal arteries.
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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[22], and these characteristics make creatinine an obvious
marker of renal function [21]. However, in some cases, plasma
creatinine and its clearance may stay within normal range even
when renal function is impaired [22]. The ratio between BUN
and creatinine is constant and approximately 10:1 in healthy
animals, and it has therefore been suggested that the ratio in
particular may be used as diagnostic biomarker in renal
dysfunction [22]. Body temperature is another key parameter to
monitor. Importantly, it should be maintained within the
normothermic range in pharmacokinetic studies, as temperature
is well known to affect metabolic turnover. Expectedly,
hypothermic rats have been shown to have a lower metabolic
rate than normothermic counterparts [23]. Moreover,
hypothermia decreases both renal and hepatic clearance. In
dogs, it has been reported that hypothermia lowers GFR as
measured by inulin and creatinine clearance [24]. Also,
indocyanine green clearance in rats has been found to be
temperature dependent. As indocyanine green is a marker for
hepatic blood flow [25], this further underlines the need for
temperature monitoring and maintenance during
pharmacokinetic studies. If not heated properly, keeping an
animal under general anaesthesia will often result in a drop in
body temperature. When performing abdominal surgery, the
temperature may drop even further due to heat loss from
the exposed abdomen. However, as shown in fig. 4, keeping the
animal normothermic during surgery and post-operative can be
challenging. The figure shows attempts on temperature control
of rats undergoing nephrectomy under continued isoflurane.
Hepatectomy
Hepatectomy refers to surgical removal of the liver. The pro-
cedure results anatomically and functionally in an anhepatic
state. Anatomically, an anhepatic state is a state without any
hepatic tissue, whereas a functionally anhepatic state refers to
the absence of functional hepatic tissue [26]. Total hepatic
devascularization is another surgical methodology used to
establish a functionally anhepatic state. Lempinen et al. [26]
have made a short historical introduction to hepatectomy and
hepatic devascularization. The use of an anhepatic state as a
model of fulminant hepatic failure has been reviewed else-
where [27].
Several species have been described in an anhepatic state.
Laboratory animals used for anhepatic studies are primarily
rats and pigs, but other species have also been used as listed
in table 3. It is worth noting that there is considerable varia-
tion in survival times depending on animal species and even
within species depending on the technique used. With up to
3 days of survival, pigs seem to be most resistant [28],
whereas studies in other species typically report survival times
of <24 hr (table 3).
As an example of the use of a hepatectomy model, a study
using hepatectomized rats reported that elimination of pento-
barbital proceeds primarily via hepatic metabolism (fig. 5).
Importantly, however, hepatectomy itself changed the volume
of distribution of pentobarbital significantly from that observed
in normal rats [11]. Hepatectomized rats have also been used
to investigate the clearance of 125I-labelled parathyroid hor-
mone (fig. 2). The study used hepatectomized and nephrec-
tomized rats to show that both kidney and liver play a role in
clearance of parathyroid hormone [12]. Some information is
also available from human beings as the temporary anhepatic
state during surgical liver transplantation has been used to esti-
mate hepatic and extrahepatic metabolism of the analgesics
[29,30] and anaesthetics [31] used. Thus, it has been reported
that in human beings, both morphine [30] and fentanyl [29]
are primarily metabolized by the liver. Another study in anhe-
patic human beings showed that extrahepatic metabolism is
the predominant in propofol clearance [31]. Here, the focus
will be on the use of laboratory animals undergoing hepatec-
tomy or hepatic devascularization as pharmacokinetic models
to assess hepatic and extrahepatic clearance.
Anatomical challenges when doing hepatectomy. There are
two main anatomical challenges when doing total hepatectomy
(fig. 6). The first is the need for portosystemic shunting. The
blood supply to the intestinal tract drains into the portal vein,
which then goes to the liver and branches into a second
capillary system. The portal vein receives about 10–25% of
the cardiac output depending on the species [32], and
occlusion or diversion of the portal vein is necessary when
performing hepatectomy to avoid massive haemorrhage and
untimely death of the animal. Simply clamping the portal vein
without portosystemic shunting will result in splanchnic
congestion, leading to ischaemic injury to the splanchnic
organs [33,34] and subsequently death of the animal. Thus,
Table 2.
Measures of monitoring typically employed in nephrectomy studies.
Species BUN Creatinine Glucose pH Temperature
Rat [12,68,69] [69] [69] [69]
Mouse [13] [13,20] [20]
Pig [70] [16,70]
Sheep [71]
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Fig. 4. Typical body temperature versus time curve of rats undergoing
nephrectomy. The figure shows data compiled from experiments
where body temperature (°C) was measured in rats undergoing
nephrectomy as well as during the post-operative period. Rats were
kept under continued isoflurane anaesthesia on a heating pad with
(unbroken line) or without temperature control (dotted line). An obvi-
ous drop in temperature is seen as long as the abdominal cavity is
opened, and the surgery is ongoing; after closure of the abdominal
incision, the body temperature slowly rises again. Better body temper-
ature control is achieved using a homoeothermic heating system.
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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Table 3.
Studies using anhepatic models species, survival time after establishment, study aim and anaesthetic agents used.
Species Survival Aim
Anaesthetic and
analgesic agents Investigators
Rat 27 hr Creation of technique and
determination survival time
Diethyl ether Meehan et al. [49]
Not reported Study of pentobarbital metabolism Not reported Ossenberg et al. [11]
Not reported Study of parathyroid hormone
metabolism
Not reported Segre et al. [12]
Hepatectomy:
5.75  0.67 hr at 37.5°C
8.51  0.78 hr at 35.5°C
Devascularization:
5.61  1.06 hr at 37.5°C
8.30  0.70 hr at 35.5°C
Comparison of hepatectomy
and devascularization
Not reported Peignoux et al. [46]
18 hr Creation of a bloodless technique Diethyl ether Holmin et al. [41]
36 hr Creation of a one-stage technique with
maintenance of gastrointestinal function
Diethyl ether Yamaguchi et al. [47]
10.63  1.60 hr Creation of a simple and easy technique Diethyl ether Omokawa et al. [50]
20  5 hr Creation of a reproducible technique
of a fulminant hepatic failure model
Diethyl ether Rozga et al. [51]
Not reported Study of brain oedema and intracranial
hypertension after hepatectomy
Methoxyflurane Olafsson et al. [48]
20  5 hr Creation of a one-stage technique
with venous graft
Diethyl ether Azoulay et al. [40]
10.5 hr (range 5.5–21.5) Creation of a one-stage
microvascular technique
Halothane Engelbrecht et al. [43]
3.93  0.42 hr Creation of technique to establish model to
evaluate the function of artificial
liver support devices
Diethyl ether Umehara et al. [44]
Not reported Study of extrahepatic metabolism Diethyl ether Ping et al. [9]
Not reported Study of extrahepatic metabolism
and gene expression
Isoflurane Gu et al. [7]
Pig 24.5 hr (range 15–40) Creation of technique Pentobarbital Lempinen et al. [26]
Hepatectomy: 16–36 hr
Devascularization: 17–28 hr
Plasma amino acid patterns
in acute hepatic failure
Pre-medication:
ketamine Induction:
ketamine Maintenance:
halothane, protoxide
Mazziotti et al. [39]
16.88  5.38 hr Creation of a reproducible technique
of a fulminant hepatic failure model
Pre-medication:
atropine, ketamine,
diazepam and azaperone
Induction: fentanyl,
ketamine and propofol
Maintenance: fentanyl
and propofol
Filipponi et al. [56]
46  6 hr Creation of technique using a
self-made, three-way prosthesis
Induction: ketamine,
azaperone, atropine and
isoflurane Maintenance:
sufentanil and ketamine
Sosef and Gulik [58]
Not reported Study of extrahepatic factor VIII expression
and plasma clearance of human FVIII
Not reported Hollestelle et al. [3]
51.2  18.7 hr Creation of a pig model without extracorporeal
circulation and prolonged post-operative survival
Induction: atropine, ketamine,
azaperone and diazepam
Maintenance: ketamine,
fentanyl and midazolam
Knubben et al. [57]
53  5 hr
74  6 hr1
Study of dummy device effects on
haemodynamics, body
temperature and survival.
Induction: atropine, ketamine,
azaperone and diazepam
Maintenance: ketamine,
fentanyl and midazolam
Thiel et al. [28]
Dog 12–20 hr Creation of one-stage technique with
end-to-end anastomosis of v. cava caudalis
Thiamylal Alican et al. [37]
5 hr Creation of a one-stage technique
without alterations in extrahepatic metabolism
Induction: thiopental
and succinylcholine
Maintenance: halothane
Daloze et al. [45]
Rabbit 4 hr Study of extrahepatic metabolism Isoflurane Nyberg et al. [10]
Sheep Not reported Pharmacokinetic study of 125I-erythropoietin Pentobarbital Widness et al. [71]
1Prolonged survival time with the use of extracorporeal circuit.
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survival time of a rat with clamped portal vein is
approximately 50 min. [35]. Portosystemic shunts can be used
to reduce the ischaemic injury caused by splanchnic
congestion [34].
The second main challenge to overcome is the close con-
nection between the v. cava caudalis (VCC) and the liver.
Some species have a long intrahepatic part of the VCC, for
example, as seen in the rat [36] and pig [26], whereas the int-
rahepatic part is very short in, for example, dogs [37]. Human
beings have a retroperitoneal VCC [36]. Removal of all liver
tissue in animals with an intrahepatic part of the VCC requires
removal of the intrahepatic part as well. Moreover, it is neces-
sary to re-establish flow in the VCC by the use of anastomosis
or prosthesis, when removing a segment of a large vein such
as the VCC [38,39].
Hepatectomy with one, two or three stages in the rat. In the
rat, interruption of the portal flow exceeding 30 min. will
result in an irreversible state of shock [33] – some even state
that rats only tolerate a maximum of 20 min. of interruption
of the portal vein flow [40,41].
A part of the VCC is completely intrahepatic in the rat. The
caudate process of the liver is closely connected to this intra-
hepatic part [36]. The caudate process constitutes approxi-
mately 2–3% of the total liver mass [36,42], and its position
makes total hepatectomy a surgical challenge, because a
venous graft or prosthesis is needed to replace the intrahepatic
part of the VCC to complete a total hepatectomy in one stage.
As mentioned above, shunting of the portal blood is absolutely
necessary to avoid splanchnic congestion, and removal of the
intrahepatic part of VCC is needed to remove 100% of the
hepatic tissue in the rat. Several different procedures have
been developed to overcome these two critical steps in hepa-
tectomy of the rat. The techniques can be grouped into one,
two or three-stage techniques, respectively (table 4).
In the one-stage technique, the entire procedure is com-
pleted in one operation with the model being established right
away. The drawback of one-stage techniques is that they often
require complex microvascular surgical skills [43]. Two- and
three-stage techniques are performed over two and three oper-
ations, respectively, with varying time intervals in between the
operations. These multistage techniques have been developed
to simplify the establishment of hepatectomy models. The
major drawbacks of two- and three-stage techniques are that
Fig. 5. Pentobarbital blood concentration verses time curve in normal
and hepatectomized rats. The figure shows a prolonged terminal half-
life of pentobarbital in the hepatectomized rat compared with the nor-
mal rat indicating that the liver is important in the clearance of pento-
barbital. Open circles and dotted line represent hepatectomized rats,
and unbroken line and filled circles represent normal rats. The figure
is modified from Ref. [11].
A
B
C
Fig. 6. Diagram of the liver and the blood vessels of interest when
performing hepatic devascularization or hepatectomy. The diagram is
based on the anatomy of the rat. (A) Normal anatomy of the liver. (B)
Hepatic devascularization with end-to-side portacaval shunt and liga-
tion of the bile duct and the hepatic artery. (C) One-stage hepatectomy
with the use of a Y-shaped graft or prosthesis and ligation of the bile
duct and the hepatic artery. 1: liver, 2: infrahepatic inferior vena cava,
3: suprahepatic inferior vena cava, 4: portal vein, 5: gastroduodenal
vein, 6: hepatic artery, 7: bile duct, 8: Y-shaped graft or prosthesis.
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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they are very time-consuming [37,44], have a high mortality
rate [40,41] and often lead to formation of adhesions and col-
laterals [37]. Moreover, it has been speculated that the time
interval between different stages allows the animal to adapt to
the situation and induction of changes in the extrahepatic
metabolism [45]. Some techniques are based on hepatectomy,
while others are based on hepatic devascularization (table 4).
The devascularization techniques have the advantage of being
able to leave the intrahepatic part of VCC intact, but serious
drawbacks include the potential release of enzymes and
ammonia from the necrotic liver and risk of having a unin-
tended continued blood supply to the liver [46].
One-stage hepatectomy or hepatic devascularization tech-
niques employ a number of different strategies to avoid
splanchnic congestion. Venous shunt of the splanchnic circula-
tion can be done in different ways using, for example, Y-
shaped graft [40], V-shaped polyethylene prosthesis [47],
side-to-side mesentericocaval shunt [43] or silicone catheter
[9], whereas others simply clamp the portal vein and accept
splanchnic congestion [7]. The procedures using Y-shaped
graft [40] and V-shaped polyethylene prosthesis [47] also
address the problem of removal of the intrahepatic part of
VCC as part of the Y-shaped graft or V-shaped prosthesis is
used to replace its intrahepatic section. In contrast, techniques
using end-to-side portacaval shunt, side-to-side mesenterico-
caval shunt or silicone catheters do not solve the issue with
the intrahepatic part of the VCC, which therefore needs to be
addressed separately. Side-to-side mesentericocaval shunts
combined with a vascular graft for the intrahepatic part of the
VCC is one solution that has been described for total hepatec-
tomy in the rat [43]. Alternatively, the combination of a hepa-
rinized silicone catheter and hepatic artery ligation has been
shown to completely block hepatic blood flow in rats resulting
in hepatic devascularization [9]. Simply clamping the portal
vein will inevitably cause splanchnic congestion, and conse-
quently, this approach should only be used for experiments
with a very limited time course. Clamping of the portal vein
is only used for hepatic devascularization in experiments in
which the intrahepatic part of the VCC is kept intact [7].
Two-stage hepatectomy or hepatic devascularization tech-
niques require longer time to establish. Published procedures
last from 2 days [48] and up to 1 month [49]. In general, two-
stage techniques are performed to allow formation of collateral
circulation to overcome the challenge with the intrahepatic
part of the VCC [49,50] and atrophy of liver lobes prior to
hepatectomy [51] or simply to ensure survival from the porta-
caval shunt before hepatectomy [12,48] or hepatic devascular-
ization [48]. Three-stage hepatectomy techniques are
performed to allow formation of collateral circulation in stage
one, while stage two is used for establishing a portacaval
shunt and stage three for performing the actual hepatectomy
[41,44]. However, even though multistage techniques are eas-
ier to perform, their severe drawbacks render the one-stage
model as the only valid hepatectomy model for use in preclini-
cal pharmacokinetics. Hepatic devascularization may be an
attractive alternative due to its simplicity, but total hepatec-
tomy should be preferred when possible.
Anaesthesia. When removing the liver – the primary
clearance organ of many anaesthetics and analgesics –
balancing anaesthesia can be a considerable challenge.
Removal of the liver raises a number of issues regarding the
drug of choice, the clearance of the chosen drug in the
anhepatic animal and the dosing intervals needed to keep the
animal anaesthetized throughout the procedure without
overdosing. Table 3 gives an overview of anaesthetic agents
used in hepatectomy studies. Many older studies used diethyl
ether that is now considered ethically questionable due to its
irritant properties and availability of alternatives such as
isoflurane, and consequently, ether is no longer used in
modern animal laboratory facilities. Generally, inhalation
anaesthetics are widely used in anhepatic models due to their
lower degree of hepatic metabolism. Thus, as an anhepatic
state only influences the effect and dosing of inhalations
anaesthetics to a limited extent, the challenging task of
managing injection anaesthetics at a state of decreased
metabolism can be avoided. Likewise in healthy human
beings, it is well known that <0.2% of an anaesthetic gas-like
isoflurane is metabolized [52]. Inhalation anaesthetics are also
preferred in studies with conscious anhepatic animals due to
their rapid and predictable clearance by exhalation compared
with the often very slow hepatic clearance of many injection
anaesthetic agents. Overall, inhalation anaesthetics should be
preferred over injectable anaesthetics in animal models of
hepatectomy due to the improved control of the anaesthetic
depth.
Monitoring. As animal welfare is a major concern when
performing animal experiments today; objective measures of
stress are needed to limit the discomfort of the animal to the
lowest possible level. The most frequently monitored
parameters in animal models of hepatectomy can be found in
table 5. Some are used for continued monitoring of the animal
during the experiment, while others are of particular interest
when evaluating the data obtained from the anhepatic animal.
Table 5
Measures of monitoring typically employed in anhepatic animal models.
Species Temperature Glucose Ammonia Creatinine Haemoglobin Bilirubin
Rat [11,41,46,50] [9,43,44,47,50,51] [40,44,46,48,51] [9] – [9,47]
Pig [28,56] [28,39,56,57] [26,28,39,56,58] [28,56–58] [28,39,56–58] [28]
Dog – – [45] [45] [45] –
Rabbit – [10] – – – –
Sheep – – – – [71] –
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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Ammonia is an important blood parameter in hepatectomy.
It is well known that high blood levels of ammonia cause
numerous changes in the body including intracranial hyperten-
sion [48,53,54], brain oedema [48,54] and ultimately cerebral
herniation, which is a common cause of death in human
beings with acute liver failure [55]. Rise in brain ammonia
concentration has been associated with development and pro-
gression of encephalopathy in awake hepatic devascularized
rats with loss of righting reflex followed by loss of corneal
reflex [54]. Blood glucose rapidly decreases after initiating an
anhepatic state and is known to shorten survival time if the
animal is not glucose supplemented. In agreement, Azoulay
and coworkers found that the mean survival time in hepatecto-
mized rats without glucose supplement was 6  0.5 hr com-
pared with 20  5 hr with glucose supplement [40]. Glucose
has been supplemented in various ways in hepatectomy mod-
els. Constant intravenous glucose infusion is most commonly
employed. Here, some adjust the amount of glucose infused to
blood glucose levels [10,28,40,43,47,56–58], while others
infuse at a constant rate without adjustments to blood glucose
levels [26,37,39,41,44–46,48,50,51]. However, less refined
methods such as intraperitoneal injections of glucose [41], in-
tragastrical injection of a single bolus of glucose [8], hourly
subcutaneous injection of glucose [49] and bolus injections of
glucose at blood sampling times [12] have also been used.
As mentioned in the nephrectomy section, body temperature
should generally be closely monitored as it influences drug
clearance per se. Moreover, body temperature is also impor-
tant to monitor in hepatectomy and hepatic devascularization
models because of its significant impact on survival time.
Thus, for example, lowering the body temperature of hepatec-
tomized rats from 37.5 to 35.5°C has been shown to increase
survival time by about 50% [46].
Clearly, the choice of animal species influences the number
and character of parameters it is possible to monitor. In partic-
ular, attention should be paid to the amount of blood drawn
from the animal to avoid causing hypovolaemia. Obviously,
the risk of causing hypovolaemia due to blood sampling is
likely to decrease with increasing animal size due to the
higher blood volume. Consequently, hypovolaemia is of par-
ticular concern in rodent hepatectomy models because of the
risk of considerable blood loss during the vascular surgery
performed. This makes haemoglobin a highly relevant parame-
ter in studies with hepatectomy models. If replacement fluid is
used, measured haemoglobin can also be used to correct for
haemodilution that would otherwise compromise in particular
pharmacokinetic studies.
Use and Limitations as Pharmacokinetic Models
Kidneys and liver are vital organs for maintaining homoeosta-
sis. Removing a vital organ will cause changes to the organ-
ism, which will likely influence the data obtained and
therefore compromise the validity of such results. The kidneys
and the liver are highly perfused organs receiving approxi-
mately 12–22% and 18–33% of cardiac output, respectively,
depending on the species [32]. Clearly, changing the blood
flow to these organs will have dramatic haemodynamic conse-
quences and may directly or indirectly influence multiple mea-
surable parameters and should therefore be taken into account
when interpreting the data obtained.
Nephrectomy. Several studies of the effect of renal failure on
extrarenal clearance have been conducted, and the subject has
been reviewed several times in the past covering different
aspects [59–62]. Touchette and Slaughter reviewed the effect of
renal failure on hepatic clearance and concluded that the
specific mechanism involved in inhibition of extrarenal
clearance during renal failure remains unclear, while the
inhibition phenomenon itself is well-established and should be
considered [59]. Recent reviews have looked more closely into
the mechanism behind this inhibition. Vilay et al. [60] proposed
that acute kidney injury affects hepatic drug metabolism and
transporter function and that these two components partly
explain the changes observed in extrarenal clearance as a result
of acute kidney injury. Sun et al. [61] reviewed the effect of
renal failure on uptake and efflux drug transporters and
concluded that the effect of renal failure on these transporters
contributes significantly to the pharmacokinetic changes
observed. Pichette and Leblond [62] suggested that a decrease
in extrarenal metabolism is due to reduction in cytochrome
P450 during chronic renal failure. A human study of individuals
with varying degrees of renal impairment clearly showed that
renal clearance of desmopressin varies with renal function as
measured by creatinine clearance. Likewise, non-renal clearance
of desmopressin was found to vary with creatinine clearance
(fig. 7) [63].
The above-mentioned changes in extrarenal clearance
observed during renal failure may question the usefulness of
nephrectomy models in pharmacokinetic studies. If the extrare-
nal clearance is affected by the model itself, then the model is
of less value. Liver perfusion studies have indicated that
Fig. 7. Non-renal and renal clearance of desmopressin and the rela-
tionship with creatinine clearance in patients with varying degree of
renal impairment. The unbroken line represents the covariate relation-
ship based on nonlinear mixed effects modelling between non-renal
clearance of desmopressin and creatinine clearance while the broken
line represents corresponding covariate relationship between renal
clearance of desmopressin and creatinine clearance. Filled circles are
individual observations of non-renal clearance, and open circles are
individual observations of renal clearance. The figure is modified from
Ref. [63].
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effects on extrarenal clearance may be caused by components
in uraemic blood [64,65]. It is worth noting that the change in
extrarenal clearance can be either increased [64] or decreased
[65,66] clearance depending on the drug. However, all the
above-mentioned changes in extrarenal clearance have been
observed during progression of renal failure or chronic renal
failure that do not necessarily resemble the situation in phar-
macokinetic studies, where data are typically collected directly
following the surgical procedure. Thus, short-term pharmaco-
kinetic studies using nephrectomized laboratory animals may
therefore still be of great value, provided that the experiments
are completed before development of uraemia and resulting
changes in extrarenal clearance.
An example of the successful use of a nephrectomy model
in studies of clearance mechanisms is provided by Moravek
and coworkers, who examined renal and non-renal clearance
of eight different drugs [5]. Although they clearly provided
interesting renal and non-renal clearance data on the drugs
tested using a large number of animals (>20 nephrectomized
rats per drug), some validation issues still need to be
addressed. Polyfructosane-S was used as a marker of glomeru-
lar filtration rate [5]. However, as no model compound of
non-renal clearance was included, the questions of model-
induced changes in non-renal and renal clearance could not be
properly addressed.
Hepatectomy. Hepatectomy is known to cause considerable
haemodynamic changes including, for example, decreased
mean arterial pressure [56–58], increased central venous
pressure [57], increased heart rate [48,57,58], decreased
oxygen saturation [57] and increased arterial blood pH [48].
Hence, if haemodynamic homoeostasis is essential for an
intended study, hepatectomy will most likely be of little or
no use due to the marked changes induced by the model
per se.
It has been reported that a portacaval shunt in normal rats
can cause changes in renal function [67]. Importantly, these
changes were observed 30 days after the portacaval shunt was
established, and the procedure did not include hepatectomy.
Regardless, the results suggest that the use of multiple stage
hepatectomy techniques may result in altered renal function
and drug clearance and thus adversely affect pharmacokinetic
studies. In agreement, Daloze et al. [45] suggested that only
one-stage hepatectomy techniques should be used to avoid
potential changes in extrahepatic metabolism.
Additional drawbacks of one-stage hepatectomy models
include the requirement for extensive surgical training (for
some models even microsurgical training) and the fact that the
animals do not survive total hepatectomy for longer periods of
time. As discussed above, the choice of species influences
these disadvantages as, for example, performing the surgical
techniques becomes increasingly difficult with decreasing size
of animal, and survival time is influenced by animal species.
While different species have varying survival time (table 3),
the observed intraspecies variation in survival time can to a
large extent be explained by the difference in the technique
employed.
However, even with these serious limitations in mind, hepa-
tectomy still remains a valuable method to evaluate hepatic
and extrahepatic metabolism in preclinical drug development
in cases where liver perfusion models and other ex vivo meth-
ods cannot be used.
An example of the successful application of a hepatectomy
model is the investigation of clearance mechanisms of plasma-
derived human FVIII in pigs [3]. This study showed that even
though the liver does play a role in the clearance of FVIII,
90% of the used FVIII dose was cleared within the first 24 hr
in hepatectomized pigs [3]. Unfortunately, this study used a
very low n-value (n = 2) and displayed an increased interindi-
vidual variation in hepatectomized compared with control ani-
mals. The experiment therefore also underlines the challenges
of conducting hepatectomy studies in pigs in general.
Conclusion
Animal models of nephrectomy and hepatectomy have consid-
erable potential in preclinical pharmacokinetic studies if used
with caution. It is essential to consider the length of the study,
that is, time from establishment of model till completion of
the data collection, because animal models of nephrectomy
and hepatectomy have a markedly reduced lifespan. Moreover,
the inclusion of proper sham-operated control groups is imper-
ative in such studies because many pathophysiological
changes potentially affecting the experimental outcome have
been described in the literature including marked haemody-
namic changes. As all relevant changes to the organism have
most likely not been described at this point, great caution
should be employed when interpreting data. The models
should be thoroughly validated before use. While the literature
describes many different techniques to establish an animal
model of hepatectomy, only very few of these techniques have
been properly validated. Thus, attempts of validation have
been carried out in some models [9], but further validation is
required when deviating from these specific techniques.
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